The Benefit and Risk of Addition of Chemotherapy to EGFR Tyrosine Kinase Inhibitors for EGFR-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases: A Meta-Analysis Based on Randomized Controlled Trials

Six databases were systematically searched for relevant literatures comparing ETC versus ET in treating EGFR-positive NSCLC patients with BM. The primary outcome assessed was overall survival (OS), while secondary outcomes included progression-free survival (PFS), and central nervous system (CNS)-PFS, responses, progression status and safety.